RBC Capital Maintains Outperform on AMETEK, Raises Price Target to $148
RBC Capital analyst Deane Dray maintains AMETEK (NYSE:AME) with a Outperform and raises the price target from $146 to $148.
AMETEK: Q1 Earnings Insights
AMETEK (NYSE:AME) reported its Q1 earnings results on Tuesday, May 3, 2022 at 06:55 AM.
Here's what investors need to know about the announcement.
Earnings
AMETEK beat estimated earnings by 4.72%, reporting an EPS of $1.33 versus an estimate of $1.27.
Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell
• Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
$100 Invested In AMETEK 20 Years Ago Would Be Worth This Much
AMETEK (NYSE:AME) has outperformed the market over the past 20 years by 9.74% on an annualized basis producing an average annual return of 16.65%. Currently, AMETEK has a market capitalization of $28.86 billion.
AMETEK Q1 2022 Earnings Conference Call On May 3, 2022 At 08:30 AM ET
AMETEK (NYSE:AME) will host a conference call at 08:30 AM ET on May 3, 2022, to discuss Q1 2022 earnings results.
How to Attend AMETEK (AME) Conference Call
Follow this link to access the live webcast.
$100 Invested In AMETEK 20 Years Ago Would Be Worth This Much
AMETEK (NYSE:AME) has outperformed the market over the past 20 years by 10.21% on an annualized basis producing an average annual return of 17.29%. Currently, AMETEK has a market capitalization of $30.33 billion.
A Bearish Sign Appears On AMETEK’s Chart
If history is any guide, there may be trouble ahead for shares of AMETEK (NYSE:AME). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.
Earnings Scheduled For February 3, 2022
Companies Reporting Before The Bell
• Tuesday Morning (NASDAQ:TUEM) is likely to report earnings for its second quarter.